Tofacitinib for the Treatment of Refractory Progressive Vitiligo: A Retrospective Case Series

Table 1

Clinical characteristics of the vitiligo patients and outcomes of tofacitinib treatment.

Patient no.	Age (y)/sex	Disease duration (y)	Location of lesion	VIDA score at baseline	Tofacitinib treatment duration (m)	Concomitant NB-UVB	VIDA score after therapy	Arrest of progression	Repigmentation
1	F/34	17	Entire body	4	5	No	3	Yes	No
2	M/33	15	Entire body	4	5	No	2	Yes	No
3	F/12	5	Limbs and crotch	4	6	1/W	2	Yes	Yes
4	F/29	2	Face, neck, chest, and arms	4	7	1/W	2	Yes	Yes
5	F/18	0.5	Neck, trunk, and hands	4	9	1/W	1	Yes	Yes
6	F/56	7	Entire body	4	9	2/W	1	Yes	Yes
7	M/26	10	Limbs and trunk	4	5	2/W	2	Yes	Yes
8	F/62	30	Entire body	4	6	1/W	2	Yes	Yes
9	M/57	8	Hands	4	4	No	2	Yes	No
10	F/46	26	Neck and limbs	4	3	1/W	3	Yes	No
11	M/26	4	Entire body	4	7	No	2	Yes	No
12	F/50	2	Face, neck, trunk, and hands	4	7	1/W	2	Yes	Yes
13	F/50	0.5	Arms	4	2	No	2	Yes	No
14	F/50	10	Entire body	4	7	1/W	3	Yes	Yes
15	M/46	3	Face and hands	4	9	No	1	Yes	Yes
16	F/49	4	Entire body	4	8	1/W	2	Yes	Yes
17	M/57	10	Scalp, face, and hands	4	4	No	4	No	No
18	F/56	18	Entire body	4	2	No	4	No	No
19	F/31	5	Scalp, face, neck, and limbs	4	3	1/W	4	No	No
20	F/40	20	Entire body	4	2	1/W	4	No	No
21	M/30	12	Face, neck, and limbs	4	2	No	4	No	No
22	F/33	7	Face, trunk, and limbs	4	2	No	4	No	No
23	M/29	6	Entire body	4	2	No	4	No	No
24	M/49	7	Trunk and limbs	4	3	No	4	No	No
25	M/21	1.5	Face, hands, feet, and crotch	4	3	No	4	No	No